Atezolizumab (MPDL3280A) inhibits the PD-L1/PD-1 pathway by binding to PD-L1 and has been approved for the treatment of advanced NSCLC, triple-negative breast cancer and urothelial carcinoma 15, 71. The gene discussed is CD274; the disease is urothelial carcinoma.